Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir
Article first published online: 10 NOV 2013
© 2013 John Wiley & Sons Ltd
Alimentary Pharmacology & Therapeutics
Volume 39, Issue 1, pages 85–92, January 2014
How to Cite
Maasoumy, B., Cobb, B., Bremer, B., Luk, K., Halfon, P., Aslam, S., Manns, M. P., Cornberg, M. and Wedemeyer, H. (2014), Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir. Alimentary Pharmacology & Therapeutics, 39: 85–92. doi: 10.1111/apt.12544
- Issue published online: 3 DEC 2013
- Article first published online: 10 NOV 2013
- Manuscript Accepted: 12 OCT 2013
- Manuscript Revised: 3 OCT 2013
- Manuscript Revised: 12 SEP 2013
- Manuscript Received: 14 AUG 2013
- 1EASL Clinical Practice Guidelines. Management of hepatitis C virus infection. J Hepatol 2011; 55: 245–64.
- 12The ExPECT study: an international multicenter clinical trial evaluating low HCV RNA viremia with the COBAS AmpliPrep/COBAS TaqMan HCV Test, v2.0 compared to assays used in routine clinical practise and in drug trials. Hepatology 2012; 56(Suppl.): 676A–7A., , , et al.
- 15Undetectable HCV-RNA in telaprevir-treated patients: low concordance between two highly sensitive real-time pcr assays. J Hepatol 2013; 58(Suppl.): 208., , , et al.